<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148898</url>
  </required_header>
  <id_info>
    <org_study_id>YC2019-S087</org_study_id>
    <nct_id>NCT04148898</nct_id>
  </id_info>
  <brief_title>Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis</brief_title>
  <acronym>OWONBNSCLCLM</acronym>
  <official_title>A Randomized Phase II Trial of Osimertinib Alone or in Combination With Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Nanchang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leptomeningeal metastasis (LM) is a devastating and terminal complication of advanced
      non-small-cell lung cancer (NSCLC), especially in patients harboring epidermal growth factor
      receptor (EGFR) mutations. Osimertinib is an oral,third-generation, irreversible epidermal
      growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both
      EGFR-TKI-sensitizing and EGFR T790M resistance mutations .AURA I/II study and other
      preclinical study suggested that Osimertinib exhibited a better blood-brain barrier(BBB)
      penetration than the other EGFR-TKIs (gefitinib, erlotinib, or afatinib).The BLOOM 、AURA and
      FLURA study demonstrated that osimertinib showed encouraging activity and manageable
      tolerability in pretreated EGFR-mutant NSCLC patients with LM. Bevacizumab is a monoclonal
      antibody against vascular endothelial growth factor (VEGF). Animal study and autopsy
      specimens showed that VEGF is an essential factor in LM. Recently study showed EGFR-TKIs plus
      bevacizumab prolonged PFS and OS in patients with EGFR-mutant NSCLC and multiple brain
      mteastasis when compared with EGFR-TKIs alone. Howerver osimertinib combined with bevacizumab
      could benefit patients with LM from EGFR- mutant NSCLC remains undetermined. Therefore, the
      purpose of the study is to evaluate the safety and efficacy of osimertinib combined with
      bevacizumab for EGFR- mutant non-small cell lung cancer with leptomeningeal metastasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase II clinical trial. The objective of the study is to assess the
      efficacy of osimertinib combined with bevacizumab for LM from EGFR- mutant NSCLC. Patients
      were randomized with equal allocation to 80 mg of oral Osimertinib daily alone or with 7.5
      mg/kg of intravenous bevacizumab every 3 weeks. Study therapy continued until disease
      progression, unacceptable adverse event, or withdrawal of consent
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Crossover Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>single</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial progression-free</measure>
    <time_frame>Every 6 weeks, up to 2 years,</time_frame>
    <description>iPFS (Time from LM diagnosis to the first documentation of intracranial lesion progression or death with documented intracranial pro- gression,)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Every 6 weeks, up to 2 years</time_frame>
    <description>ORR, proportion of patients with a best overall response of complete response or partial response (CR+PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LM Overall survival</measure>
    <time_frame>Every 3 weeks, up to 5 years,</time_frame>
    <description>LM-OS defined as time from LM diagnosis to death due to any cause or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>Every 6 weeks, up to 2 years,</time_frame>
    <description>Proportion of patients progression-free by investigator assessment per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>Every 3 weeks, up to 2 years,</time_frame>
    <description>Number of patients with adverse events (AEs) as a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Leptomeningeal Metastasis</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>EGFR Activating Mutation</condition>
  <arm_group>
    <arm_group_label>osimertinb group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Osimertinib 80 mg oral daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>osimertinb combined with bevacizumab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Osimertinib 80 mg oral daily;
.bevacizumab 7.5 mg/kg intravenous every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Treatment of LM With osimertinb</description>
    <arm_group_label>osimertinb combined with bevacizumab group</arm_group_label>
    <arm_group_label>osimertinb group</arm_group_label>
    <other_name>AZD9291</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Treatment of LM With osimertinb combined with bevacizumab</description>
    <arm_group_label>osimertinb combined with bevacizumab group</arm_group_label>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age in 18-80 years

          -  Pathologically proven NSCLC

          -  EGFR mutation , the EGFR status was identified from primary lung tumors using the
             amplification refractory mutation system (ARMS) or next-generation sequencing (NGS)
             analysis.

          -  LM diagnosis was based on the detection of malignant cells in the CSF, the focal or
             diffuse enhancement of leptomeninges, and nerve roots or the ependymal surface on
             gadolinium-enhanced MRI .

          -  No severe abnormal liver and kidney function;

          -  No other severe chronic diseases;

          -  Signed informed consent form

        Exclusion Criteria:

          -  Patients with the clinical manifestation of nervous system failure including severe
             encephalopathy, grade III-IV white matter lesions confirmed by imaging examination,
             moderate or severe coma, and glasgow coma score less than 9 points;

          -  Allergic to osimertinib or bevacizumab

          -  Any of the following: Pregnant women ;Nursing women ;Men or women of childbearing
             potential who are unwilling to employ adequate contraception

          -  History of myocardial infarction or other evidence of arterial thrombotic disease
             (angina), symptomatic congestive heart failure (New York Heart Association ≥ grade 2),
             unstable angina pectoris, or cardiac arrhythmia; Note: allowed only if patient has no
             evidence of active disease for at least 6 months prior to randomization;

          -  History of cerebral vascular accident (CVA) or transient ischemic attack (TIA)≤ 6
             months prior to randomization

          -  History of bleeding diathesis or coagulopathy

          -  History of hemoptysis da≥ grade 2 (defined as bright red blood of at least 2.5 mL) ≤3
             months prior to randomization

          -  Leukocytes below 2*10^9/L, neutrophils below 1*10^9/L; platelets below 50*10^9/L;

          -  Had major surgery within 60 days;

          -  History of arteriovenous thrombosis

          -  Gastrointestinal perforator in the past 6 months

          -  Inadequately controlled hypertension (systolic blood pressure of &gt; 150 mmHg or
             diastolic pressure &gt; 100 mmHg on anti-hypertensive medications); Note: history of
             hypertensive crisis or hypertensive encephalopathy not allowed

          -  Grade 4 proteinuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liu Anwen, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Second Affiliated Hospital of Nanchang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu Anwen, Phd</last_name>
    <phone>+8613767120022</phone>
    <email>awliu666@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cai Jing, Phd</last_name>
    <phone>+8615270905381</phone>
    <email>cjdl879@163.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Cai Z, Liu Q. Understanding the Global Cancer Statistics 2018: implications for cancer control. Sci China Life Sci. 2019 Aug 26. doi: 10.1007/s11427-019-9816-1. [Epub ahead of print]</citation>
    <PMID>31463738</PMID>
  </reference>
  <reference>
    <citation>Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC, Shih JY, Yu CJ, Yang JC. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. J Thorac Oncol. 2015 Dec;10(12):1754-61. doi: 10.1097/JTO.0000000000000669.</citation>
    <PMID>26334749</PMID>
  </reference>
  <reference>
    <citation>Zhou Q, Song Y, Zhang X, Chen GY, Zhong DS, Yu Z, Yu P, Zhang YP, Chen JH, Hu Y, Feng GS, Song X, Shi Q, Yang LL, Zhang PH, Wu YL. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). BMC Cancer. 2017 Jul 3;17(1):462. doi: 10.1186/s12885-017-3451-x.</citation>
    <PMID>28673332</PMID>
  </reference>
  <reference>
    <citation>Wu YL, Zhao Q, Deng L, Zhang Y, Zhou XJ, Li YY, Yu M, Zhou L, Zou BW, Lu Y, Liu YM. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer. Lung Cancer. 2019 Jan;127:1-5. doi: 10.1016/j.lungcan.2018.11.022. Epub 2018 Nov 20.</citation>
    <PMID>30642536</PMID>
  </reference>
  <reference>
    <citation>Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol. 2018 Jan;19(1):e43-e55. doi: 10.1016/S1470-2045(17)30689-7. Review.</citation>
    <PMID>29304362</PMID>
  </reference>
  <reference>
    <citation>Reijneveld JC, Taphoorn MJ, Kerckhaert OA, Drixler TA, Boogerd W, Voest EE. Angiostatin prolongs the survival of mice with leptomeningeal metastases. Eur J Clin Invest. 2003 Jan;33(1):76-81.</citation>
    <PMID>12492456</PMID>
  </reference>
  <reference>
    <citation>Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016 Oct 15;22(20):5130-5140. Epub 2016 Jul 19.</citation>
    <PMID>27435396</PMID>
  </reference>
  <reference>
    <citation>Jiang T, Chu Q, Wang H, Zhou F, Gao G, Chen X, Li X, Zhao C, Xu Q, Li W, Wu F, Xiong A, Zhao J, Xu Y, Su C, Ren S, Zhou C, Hirsch FR. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. Int J Cancer. 2019 May 15;144(10):2605-2612. doi: 10.1002/ijc.31962. Epub 2018 Dec 8.</citation>
    <PMID>30387880</PMID>
  </reference>
  <reference>
    <citation>Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018 Sep 10;36(26):2702-2709. doi: 10.1200/JCO.2018.77.9363. Epub 2018 Jul 30.</citation>
    <PMID>30059262</PMID>
  </reference>
  <reference>
    <citation>Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rudà R, Preusser M; EANO Executive Board and ESMO Guidelines Committee. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017 Jul 1;28(suppl_4):iv84-iv99. doi: 10.1093/annonc/mdx221.</citation>
    <PMID>28881917</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leptomeningeal metastasis</keyword>
  <keyword>non small cell lung cancer</keyword>
  <keyword>EGFR Activating Mutation</keyword>
  <keyword>Osimertinib</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

